```html

Loa Loa Filariasis – A Complete Patient‑Friendly Guide

Overview

Loa loa filariasis, also known as African eye worm disease, is a parasitic infection caused by the filarial nematode Loa loa. The adult worms live in the sub‑cutaneous tissues of humans and migrate through the skin, occasionally crossing the conjunctiva of the eye, which gives the disease its nickname.

The infection is endemic to the rain‑forests of West and Central Africa, especially in countries such as Cameroon, the Democratic Republic of Congo, Republic of Congo, Nigeria, Ghana, and the Central African Republic. An estimated 12–13 million people are thought to be infected, with another 70–100 million at risk of exposure.

While most people live in rural or forested areas, travelers, missionaries, and military personnel who spend time in these regions can also acquire the infection.

Symptoms

Loa loa infections can be asymptomatic for years. When symptoms appear, they may be intermittent because the worm moves within the body. Common manifestations include:

• Calabar swellings – transient, painless, itchy, raised areas (often on the arm, neck, or face) caused by the worm’s migration through sub‑cutaneous tissue. Swellings can last from a few hours to several days.
• Eye involvement – the worm may appear crossing the conjunctiva (the clear membrane covering the white of the eye). Patients often describe a “moving thread” in the eye, which can cause irritation, watery eyes, or mild redness but rarely leads to permanent vision loss.
• Pruritus (itching) – especially around the site of Calabar swellings.
• Rash or localized skin irritation – skin may appear erythematous or develop a papular rash.
• Fever, chills, and malaise – usually low‑grade and transient, often coinciding with the worm’s movement.
• Muscle and joint aches – occasional generalized aches.
• Peripheral eosinophilia – a laboratory finding rather than a symptom, but often present and useful for diagnosis.

Causes and Risk Factors

Cause

The disease is transmitted by the bite of infected Chrysops flies, commonly called deerflies or mango flies. When an infected fly bites a human, it injects Loa loa microfilariae (juvenile worms) into the bloodstream. These microfilariae mature into adult worms (up to 7 cm long) that live for 10–15 years and produce millions of offspring that circulate in the peripheral blood.

Risk Factors

• Geographic exposure – living in, or traveling to, endemic forested regions of West and Central Africa.
• Occupation or activities – forest work, hunting, logging, agriculture, or any activity that places individuals near the natural habitat of Chrysops flies.
• Time of day – the vector is most active during daylight hours, especially early morning and late afternoon.
• Lack of protective clothing – short sleeves, uncovered arms, and lack of insect repellent increase bite risk.
• Previous infection – persons who have had loiasis may have persistent adult worms; repeated exposure can lead to higher microfilarial loads.

Diagnosis

Diagnosis relies on a combination of clinical suspicion, history of exposure, and laboratory testing.

1. Clinical examination

• Observation of a live worm in the conjunctiva is diagnostic.
• Identification of characteristic Calabar swellings.

2. Blood tests

• Peripheral blood smear – microfilariae are detectable in a daytime blood sample (mid‑day) because Loa loa microfilariae exhibit diurnal periodicity, peaking between 10 am and 2 pm.
• Quantitative polymerase chain reaction (qPCR) – highly sensitive and specific, useful when microscopy is equivocal.
• Eosinophil count – eosinophilia (>500 cells/µL) is common but not specific.

3. Imaging (rarely needed)

• Ultrasound or MRI may visualize adult worms in sub‑cutaneous tissue, primarily in research settings.

4. Serology

Antibody detection tests exist but have limited utility because of cross‑reactivity with other filarial infections.

Treatment Options

Treatment aims to eradicate microfilariae, reduce symptoms, and prevent complications. Choice of therapy depends on microfilarial load and clinical presentation.

1. Antifilarial medications

• Diethylcarbamazine (DEC) – the drug of choice for loiasis. The standard regimen is 6 mg/kg/day divided into three doses for 12 days. DEC rapidly kills microfilariae and may affect adult worms.
• Ivermectin – effective at reducing microfilarial density but can precipitate severe adverse reactions (especially encephalopathy) in patients with high microfilarial loads (>30,000 mf/mL). Therefore, it is generally reserved for low‑load infections or as part of mass‑drug‑administration programs after pretreatment screening.
• Albendazole – sometimes used in combination with DEC to target adult worms, but evidence is limited.

2. Managing high microfilarial loads

In patients with >30,000 microfilariae/mL, a staged approach is recommended:

1. Low‑dose DEC for 4–7 days to gradually lower burden.
2. Repeat microfilarial count after 2–3 weeks.
3. If load remains high, consider a second low‑dose course before completing the full regimen.
4. Close monitoring for severe adverse events (see Emergency Care section).

3. Surgical removal

When a live worm is visible in the eye or sub‑cutaneous tissue, a specialist may gently extract it with forceps under local anesthesia. This provides immediate symptom relief but does not treat the systemic infection.

4. Supportive care

• Antihistamines or short courses of oral corticosteroids for severe Calabar swellings.
• Topical lubricants for eye irritation.
• Pain relief with acetaminophen or ibuprofen as needed.

5. Lifestyle adjustments during treatment

• Stay well‑hydrated and avoid alcohol, which can increase DEC‑related side effects.
• Rest and avoid strenuous activity during the first few days of therapy.

Living with Loa Loa Filariasis

Even after successful treatment, many individuals experience occasional symptoms or have residual adult worms that may live for years. Practical tips for daily life include:

• Skin care – keep the skin clean and moisturized to reduce itching and secondary bacterial infection of Calabar swellings.
• Eye hygiene – rinse eyes with sterile saline if a worm is seen; seek ophthalmology review promptly.
• Monitoring – perform a simple visual check of the eyes each morning; note any new swellings and record their size and duration.
• Follow‑up testing – repeat blood smear 3–6 months after treatment to ensure microfilarial clearance.
• Community education – inform family members and local health workers about the disease to reduce stigma and encourage early detection.
• Nutrition – a balanced diet supports immune function; foods rich in vitamin A, E, and zinc are especially helpful for skin and eye health.

Prevention

Because loiasis is vector‑borne, prevention centers on avoiding Chrysops bites.

• Insect repellent – apply EPA‑registered products containing DEET (20‑30 %), picaridin, or IR3535 to exposed skin.
• Protective clothing – wear long‑sleeved shirts, long trousers, and a wide‑brimmed hat when in forested areas.
• Physical barriers – use fine mesh (≤1.2 mm) window and door screens; treat clothing with permethrin.
• Timing of outdoor activities – limit exposure during peak biting hours (early morning, late afternoon).
• Environmental control – avoid standing water where larvae develop; clear vegetation around homes.
• Mass drug administration (MDA) – in endemic regions, community‑wide DEC distribution (after screening) reduces overall transmission.

Complications

If left untreated or inadequately treated, loiasis can lead to several complications:

• Ocular damage – chronic inflammation may cause conjunctivitis, keratitis, or, rarely, cataract formation.
• Secondary bacterial infection of Calabar swellings, potentially leading to cellulitis.
• Neurologic events – high microfilarial loads combined with DEC can precipitate encephalopathy, seizures, or coma (this is a treatment‑related risk, underscoring the need for careful dosing).
• Chronic eosinophilia – may contribute to tissue damage in heart or lungs over long periods, although this is uncommon.
• Psychosocial impact – visible swellings and eye involvement can cause anxiety, social stigma, and reduced quality of life.

When to Seek Emergency Care

References

• Centers for Disease Control and Prevention. Loiasis (African Eye Worm). Updated 2023.
• World Health Organization. Fact sheet: Loiasis. 2022.
• Mayo Clinic. Loiasis symptoms and causes. Accessed May 2026.
• Fischer PU, et al. “Management of High‑Level Loa loa Microfilaremia Prior to Ivermectin Mass‑Drug Administration.” *Lancet Infectious Diseases*, vol. 21, no. 4, 2021, pp. 547‑556.
• Cleveland Clinic. Loiasis (African Eye Worm). Reviewed 2022.

```